Galapagos and Opsona Therapeutics initiate drug discovery collaboration

22-Apr-2009 - Belgium

Galapagos NV announced that it has initiated an integrated drug discovery collaboration with Opsona Therapeutics. Under the terms of the agreement, Galapagos' service division BioFocus DPI will perform biology, medicinal chemistry and ADME/PK services for an Opsona drug discovery program. Opsona will make research payments to BioFocus DPI and fund the work of 4 to 5 BioFocus DPI scientists in 2009.

"We are pleased to add Opsona Therapeutics, an emerging biotech with a promising pipeline and a successful follow-on financing round, to the growing list of BioFocus DPI customers," said Onno van de Stolpe, CEO of Galapagos. "BioFocus DPI continues to attract top biotech, pharma and not-for-profit organizations as partners, resulting in one of the most well-rounded client bases in the business."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances